Showing 1 - 10 of 324,722
Persistent link: https://www.econbiz.de/10012433847
Persistent link: https://www.econbiz.de/10010512063
evaluates the three primary barriers to employing compulsory licenses for pharmaceuticals underscored by members during TRIPS …Under Articles 31 and 31bis of the TRIPS Agreement, WTO members may validly sanction the use of a patented invention … without the patent owner's authorization by issuing a compulsory license (CL). In the pharmaceuticals space, governments have …
Persistent link: https://www.econbiz.de/10013469578
Doha Declaration further clarified and reaffirmed the existing TRIPS flexibilities. This paper argues that India has taken …-Related Aspects of Intellectual Property Rights (TRIPS Agreement), however, included a number of public health flexibilities in order … the lead role in enacting the TRIPS Agreement's substantive and procedural patent flexibilities by introducing unique …
Persistent link: https://www.econbiz.de/10013258010
experiences of Thailand and India in implementing TRIPS and using TRIPS flexibilities such as compulsory licensing to ensure … Aspects of Intellectual Property Rights (TRIPS). Given its impending transition from LDC status, there is a need to balance … affordable generic medicines when it starts granting patents for pharmaceuticals. It systematically compares Cambodia's IP laws …
Persistent link: https://www.econbiz.de/10014541559
The major bone of contention between the developed and developing countries in the TRIPS negotiations was patents for … pharmaceuticals. The US-led developed countries bloc argued in favour of patents for pharmaceuticals amidst opposition from Brazil …, India and other countries. Ample evidence, including patented AZT for HIV/AIDS treatment, showed that patents could make …
Persistent link: https://www.econbiz.de/10013393634
This paper provides an analysis of patents covering selected antibodies and vaccines used in the treatment or prevention of COVID-19. The aim of the report is to support national patent offices and interested parties in developing countries with information that can serve as guidance for the...
Persistent link: https://www.econbiz.de/10014233696
Are IPRs institutions meant to foster innovative activities or conversely to secure appropriation and profitability? Taking stock of a long-term empirical evidence on the pharmaceutical sector in the US, we can hardly support IPRs intended as an innovation rewarding institution. According to our...
Persistent link: https://www.econbiz.de/10012604733
This paper evaluates the effects of patent protection on pharmaceutical innovations for twenty-six countries that established pharmaceutical patent laws during 1978-2002. Controlling for country characteristics through matched sampling techniques to establish two proper comparison sets among...
Persistent link: https://www.econbiz.de/10012751759